🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Clinical Trials in Egypt / NCT06689241
Recruiting Not applicable

Rivaroxaban Versus Enoxaparin for Prophylaxis of Venous Thromboembolism in Bariatric Surgery

NCT06689241 · tracked via the Priya Life Science Egypt tracker
Phase
Not applicable
Started
2024-10-01
Last updated
2025-04-22

Condition(s) studied

Morbid ObesityBariatric Surgery Candidate

Investigational drug(s) / intervention(s)

Enoxaparin →rivaroxaban →

Enoxaparin: 40mg

rivaroxaban: 10mg

Study summary

Rivaroxaban versus enoxaparin for prophylaxis of venous thromboembolism in morbidly obese patients undergoing bariatric surgery: An open\_label randomized controlled trial

Eligibility

Sex
ALL
Min age
20 Years
Max age
60 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Age: 20-60 years, both sexes. * ASA physical status class I to III. * BMI 35-50 kg/m² Exclusion Criteria: * Severe cardiac disorder * chronic renal failure * liver cirrhosis * major psychological disorder

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Alexandria University Alexandria Egypt Recruiting

On this site

📄 Xarelto (rivaroxaban) drug profile →

More Alexandria University trials in Egypt

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06689241 on ClinicalTrials.gov ↗ ← All trials in Egypt